Search   |   Print Page   |   Contact Us   |   Sign In   |   Join
Community Search
Advances in Diabetes Care
View Registrations Tell a Friend About This EventTell a Friend

Advances in Diabetes Care - Key insights on tackling the diabetes pandemic and the great work underway to drive true advances in diabetes care

When: June 3, 2019
5:30-8:30 PM
Where: Regis College, Fine Arts Center
235 Wellesley St
Weston, Massachusetts  02493
United States
Contact: Bill Munger

Online registration is closed.
« Go to Upcoming Event List  

Advances in Diabetes Care
June 3 - Monday

Diabetes Clinical Update
New insights on both Type 1 Diabetes and Type 2 Diabetes from the perspective of a leading clinical researcher. Robert Gabbay, MD, PhD, FACP, the Chief Medical Officer of the Joslin Diabetes Center, will moderate our program, and he will provide an overview of the best clinical practices in diabetes care today, as well as the challenges involved in helping people with diabetes to effectively manage their diabetes.

Smart Devices and Wearables
How connected health is impacting care, medication and insulin titration and adherence, and clinical and economic outcomes for payers, providers, employers, etc. James White, MS, the co-founder of Common Sensing, a smart insulin pen company, will describe the advances underway in using real time glucose information to help patients and their care teams to optimize diabetes management to drive better clinical and economic outcomes.

Artificial Pancreas and AI
Closed loop systems, AI and cloud base diabetes decision support tools, and telemedicine/remote monitoring solutions. Trang Ly, MD, PhD, the Chief Medical Officer at Insulet, will discuss how continuous glucose monitor (CGM) systems, with smart AI and closed loop algorithms, will provide patients with a worry free "artificial pancreas" that will mimic a normal pancreas, helping keep people with diabetes in control of their blood glucose levels.

Advancements in Encapsulation
Creating an environment for new beta cells to thrive, responding to glucose and producing insulin, and being protected from the immune system. Linda Tempelman, PhD, CEO, Giner Life Sciences, will discuss how encapsulization devices can provide a nourishing and protected environment utilizing an oxygen delivery technology for use with a fully-implanted Type I Diabetes (T1D) cell therapy treatment employing immune-isolation capsule technology for allogenic pancreatic islets or stem-cell derived pancreatic islet-like cell clusters.

June 3 - Monday
Regis College
Weston, MA

Key insights on tackling
the diabetes pandemic and the
great work underway to drive
true advances in diabetes care

Earlybird Fees by May 27
 Member/Alliance Partner - $30
   Non-member - $45
   Student (member) - $10
   Student (non-member) - $15
Gold Member - No Charge
Event Sponsors

Who Should Attend: 
  • Healthcare Executives in Diabetes and Chronic Disease
  • Digital/Connected Health
  • Healthcare AI and Support Providers
  • Medical Device Entrepreneurs
  • Investors in the MedTech Space
Panel Bios
Robert A. Gabbay, MD, PhD, FACP
Chief Medical Officer and Senior Vice President, Joslin Diabetes Center, Harvard Medical School
Dr. Gabbay’s focus is to foster innovation within the walls of Joslin as well as disseminating these approaches regionally, nationally, and internationally. With over 20 years of clinical and research experience, his research focuses on innovative technologies using decision support systems, glucose monitoring technology and digital health tools to support outcomes.

Dr. Gabbay is committed to providing solutions to population health systems to ultimately to improve the lives of those with diabetes. He is dedicated to creating a model for the patient-centered medical neighborhood for diabetes, a compliment to his patient centered medical home research. The medical neighborhood will ensure patient centered coordinated care between the team of health professionals that are required to meet the patient’s needs.

James White, MS
Co-Founder and Chairman, Common Sensing
James White supports hiring, fundraising, and business models as Chairman at Common Sensing, a company that helps people use injectable medicine with daily support solutions and data feedback. James became interested in healthcare processes at the MIT Bioinstrumentation Lab, where he spent his Master’s program. Engineer turned startup executive, James is most passionate creating devices and systems that close information gaps and improve outcomes of complicated processes, like titrating insulin doses.

Gocap, James’s first invention and Common Sensing’s flagship product, monitors injection pen dosing at home and shares the logbook with clinicians and caretakers. Targeted dosing data is expected to improve decision making and outcomes and make everyday treatment more convenient.

Trang Ly, MD, PhD
Senior Vice President and Medical Director, Insulet Corporation
Dr. Trang Ly serves as Senior Vice President and Medical Director at Insulet Corporation. Dr. Ly leads the Omnipod Horizon Automated Glucose Control clinical program. Dr. Ly is a leading expert in artificial pancreas and diabetes technologies. Most recently, she served as Clinical Assistant Professor in the Division of Pediatric Endocrinology, Stanford University School of Medicine.
Prior to her time at Stanford, Dr. Ly was Pediatric Endocrinologist in the Department of Endocrinology and Diabetes at Princess Margaret Hospital for Children in Perth, Australia. Dr. Ly holds a Bachelor of Medicine and Surgery and a PhD in Pediatrics from the University of Western Australia. She is also a fellow of the Royal Australasian College of Physicians, with specialist qualification in Pediatric Endocrinology.
Linda Tempelman, PhD  
CEO, Giner Life Sciences
Linda Tempelman is a founder of Giner Life Sciences, developing oxygenated cellular therapy products with the initial product being for the treatment of diabetes. She is leading the business development, licensing and fundraising activities.ition and understand the business of healthcare in order to be successful.  
Prior to founding Giner Life Sciences, she was the Director of Biomedical R&D for Giner, Inc. bringing in over $12 million in SBIR research grants, including for the development of the commercial Giner transdermal alcohol monitor. She is an inventor on seven issued U.S. patents. She has over 30 years of experience in biotechnology and its commercial development.

John Brooks
CEO Healthcare Capital LLC
MDG Advisory Board Member
Lynn Kibblehouse
Account Executive
Boston NAMSA

Fees - (Light dinner included)
Fee Category Early Registration
(By May 27)
Week Prior
(May 27 - June 3)

At the Door
(June 3
Member/Alliance Partner: $30 $35 $45
Non-Member: $45 $55 $65
Student Member $10 $12 $15    
Student Non-member w/ a valid ID $15 $18 $20 
Gold Member No Charge No Charge  No Charge 

more MDG Calendar

Human-Centered Medical Device Design for Global Health

MDG Boston Sponsors


 Medical Development  Group
 POB 555
 Concord, MA 01742







 About Us
 Terms of Use
 Privacy Policy








Association Management Software Powered by YourMembership  ::  Legal